Global Crohn’s Disease Drugs Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Crohn’s Disease Drugs Sales Market Report 2024
Market Analysis and InsightsGlobal Crohn’s Disease Drugs Market
Crohn’s disease (CD) is a form of inflammatory bowel disease (IBD), which is comprised of two chronic autoimmune diseases that cause intestinal inflammationCrohn’s disease (CD) and ulcerative colitis (UC). The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission.
Due to the COVID-19 pandemic, the global Crohn’s Disease Drugs market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Anti-Inflammatory accounting for % of the Crohn’s Disease Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Crohn’s Disease Drugs market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Crohn’s Disease Drugs include Bayer AG, Amgen, Takeda Pharmaceutical, AbbVie, UCB, Ferring, Eli Lilly, Hoffman-La Roche and Bristol-Myers Squibb, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Crohn’s Disease Drugs Scope and Market Size
The global Crohn’s Disease Drugs market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Crohn’s Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Anti-Inflammatory
Immune system suppressors
Antibiotics
Others
Hospitals
Clinics
Hospitalshospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Bayer AG
Amgen
Takeda Pharmaceutical
AbbVie
UCB
Ferring
Eli Lilly
Hoffman-La Roche
Bristol-Myers Squibb
Pfizer
Crohn’s disease (CD) is a form of inflammatory bowel disease (IBD), which is comprised of two chronic autoimmune diseases that cause intestinal inflammationCrohn’s disease (CD) and ulcerative colitis (UC). The pathophysiology of CD is complex, as the disease is characterized by recurring flares that evolve along with periods of inactivity and remission.
Due to the COVID-19 pandemic, the global Crohn’s Disease Drugs market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Anti-Inflammatory accounting for % of the Crohn’s Disease Drugs global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospitals segment is altered to an % CAGR throughout this forecast period.
The United States Crohn’s Disease Drugs market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Crohn’s Disease Drugs include Bayer AG, Amgen, Takeda Pharmaceutical, AbbVie, UCB, Ferring, Eli Lilly, Hoffman-La Roche and Bristol-Myers Squibb, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Crohn’s Disease Drugs Scope and Market Size
The global Crohn’s Disease Drugs market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Crohn’s Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Anti-Inflammatory
Immune system suppressors
Antibiotics
Others
Segment by Application
Hospitals
Clinics
Hospitalshospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Bayer AG
Amgen
Takeda Pharmaceutical
AbbVie
UCB
Ferring
Eli Lilly
Hoffman-La Roche
Bristol-Myers Squibb
Pfizer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices